一例头孢曲松诱导的假性胆囊结石及相关文献复习
A Case of Pseudo Gallstones Induced by Ceftriaxone and Related Literature Review
DOI: 10.12677/acm.2024.1461912, PDF, HTML, XML,   
作者: 陈 力:青岛大学附属医院消化内科,山东 青岛;顾 鹏:青岛市市立医院消化内科,山东 青岛
关键词: 胆囊结石头孢曲松假结石Gallbladder Stones Ceftriaxone Pseudo Gallstones
摘要: 目的:提高临床工作者对头孢曲松致胆囊假性结石的认识,提高医疗质量。方法:对青岛大学附属医院医院1例头孢曲松引起胆囊假性结石的案例进行分析并复习相关文献。结果:患者在连续静脉使用头孢曲松钠(2 g/d) 15天内,因肺部感染复查胸部CT时无意间发现胆囊结石,但患者本身无消化道症状,停用头孢曲松1个月后复查腹部B超胆囊结石消失。结论:头孢曲松致胆囊假性结石的发生率较高,多见于大剂量长疗程使用,大多数患者无症状,因胆囊结石可于1~2个月内自行消失,一般不需要特殊处理。
Abstract: Objective: To enhance the understanding of clinical workers about pseudo gallstones caused by ceftriaxone and improve the quality of medical treatment. Method: A case of pseudo gallstones caused by ceftriaxone in The Affiliated Hospital of Qingdao University was analyzed and relevant literature was reviewed. Result: Within 15 days of continuous intravenous use of ceftriaxone (2 g/d), the patient accidentally developed gallstones during chest CT examination during pulmonary infection. Because of the patient had no digestive symptoms, she stopped using ceftriaxone for 1 month. The gallstones disappeared during abdominal ultrasound examination. Conclusion: The incidence of pseudo-gallstones caused by ceftriaxone is relatively high, often seen in high-dose and long-term use. Most patients have no symptoms, as gallstones can disappear on their own within 1~2 months and generally do not require special treatment.
文章引用:陈力, 顾鹏. 一例头孢曲松诱导的假性胆囊结石及相关文献复习[J]. 临床医学进展, 2024, 14(6): 1296-1301. https://doi.org/10.12677/acm.2024.1461912

1. 引言

头孢曲松是一种强效的半合成头孢菌素,对多种革兰阳性及革兰阴性菌有较强的杀菌活性,是当下临床应用比较广泛的抗菌药物之一。然而,由于药典、教科书及药品说明书均未提及头孢曲松对胆道系统的副作用,故在临床上可能对头孢曲松诱发的胆囊结石缺乏认识而致误诊和误治。事实上,早在1986年,Schaad等[1]就首次报道了头孢曲松钠可诱发胆囊结石,因其“可逆”特性,又被称为“假结石症”,其发病率在成人为4%~25%,在儿童中更是高达8%~46% [2]

近年来,随着头孢曲松在临床应用的愈加广泛,头孢曲松相关的“假性胆囊结石”的发生率持续升高[3]-[6],这逐渐引起了临床医师的重视,本文通过对头孢曲松形成假性胆囊结石进行报道并对结石形成的机制、结石的特点、及预后等做详细复习,以促进临床医师对“假结石”的重视,采取正确有效的应对措施。

2. 临床资料

患者吴某,女,47岁,既往轻度贫血病史,因“间断右上腹痛20余天”于2023-07-07就诊,我院CT平扫及消化系统超声均提示胆总管下端结石并胆系轻度扩张、胆囊炎(图1(a)图1(b)),急诊血常规提示:白细胞计数8.72 × 109/L,中性粒细胞百分比70%,血红蛋白95 g/L,C反应蛋白 < 0.50 mg/L,肝功示总胆红素22.57 μmol/L,直接胆红素9.64 μmol/L,血清谷丙转氨酶91 U/L,血清谷草转氨酶120 U/L,谷氨酰转肽酶300 U/L,碱性磷酸酶205 U/L。血清淀粉酶及脂肪酶均正常。给与头孢曲松2 g/d抗感染,谷胱甘肽、复方甘草酸苷保肝等治疗,建议患者行内镜下逆行性胰胆管造影取石术(ERCP),患者拒绝。到我院后第3日,患者腹痛减轻,进一步完善磁共振胰胆管成像(MRCP) (图2)及复查消化系统超声发现胆总管结石自行排出,复查肝功好转:总胆红素19.12 μmol/L,直接胆红素6.82 μmol/L,血清谷丙转氨酶34 U/L,血清谷草转氨酶23 U/L,谷氨酰转肽酶164 U/L,碱性磷酸酶133 U/L。但因患者又出现肺部感染、咳嗽,遂继续头孢曲松2 g/d抗感染。至到我院第9日,患者再次出现腹痛,复查腹部CT提示胰腺渗出,胆囊尚无异常(图1(c)),继续头孢曲松2 g/d抗感染,并加用奥曲肽抑制胰腺分泌,腹痛很快得到控制。至到我院第15天,复查胸部CT意外发现胆囊内云絮状高密度影(图1(d)图1(e)),遂停用头孢曲松。但肺部感染未完全好转,改为莫西沙星进一步治疗,后患者好转出院,出院后1个月于当地复查消化系统超声未再发现胆系异常。

(a) (b) (c)

(d) (e)

Figure 1. CT scans

1. CT扫描

Figure 2. MRCP

2. 磁共振胰胆管成像

3. 讨论

3.1. 头孢曲松所致胆囊结石的发生机制

目前对于头孢曲松引起胆囊结石的机制尚未完全明确,其可能的机制包括:

1) 头孢曲松在胆汁内的高浓度:头孢曲松在人体内不能被代谢,约40%的药物以原型经胆汁排出,60%以原型自尿中排出,故其在胆囊及肾脏中的浓度较高[7]。动物实验发现,随着胆汁在胆囊中的浓缩,头孢曲松在胆汁中的浓度相当于在血液中的20~150倍[8];我国汪复主编《实用抗感染治疗学》中提到,头孢曲松的胆汁/血液药物浓度比例为10 [9]

2) 头孢曲松与钙离子的亲和力:Park [8]等分析了头孢曲松相关结石患者的胆囊内容物,这些患者接受了胆囊切除手术,值得注意的是,在这些患者的胆囊内没有发现传统意义上的大块固体结石,取而代之的是大小约20~250微米的微细沉淀物。这些沉淀物仅含少量胆固醇晶体(1.7%)和胆色素(13.9%)颗粒,其主要成分经进一步的薄层色谱、高效液相色谱法和电子探针分析,发现96.4%是头孢曲松钙盐,其余3.6%由粘蛋白和其他蛋白组成。基于此,研究人员推测分析,在临床上广泛应用的头孢曲松钠是一种带负电荷的有机阴离子,与钙离子有较高的亲和力,二者互相结合形成不溶性钙盐沉淀,随着胆汁的浓集沉淀物逐渐增多,进而形成泥沙或结石[5] [10] [11]。有趣的是,没有其他阴离子药物或其他头孢菌素导致胆汁沉淀的数据。

3) 胆囊收缩功能降低:头孢曲松本身可以导致胆囊收缩能力的下降:通过观察不同药物对动物离体胆囊功能的影响,Arpacik等[12]发现在应用头孢曲松钠后,胆囊对组胺、胆碱的最大收缩反应减弱,这可能是引起胆囊结石的重要原因。Araz等[13]和Ozturk [14]等通过对头孢曲松钠引起的胆囊结石患儿研究,发现夏季高温脱水、体液丢失会促使胆泥淤积的形成。Meng等[15]也提出了相似的看法。

4) 尿苷二磷酸葡萄糖醛酸转移酶(UDP-Glucuronosyltransferase, UGT) 1A1基因表达异常:UGT1A1基因编码的尿苷二磷酸葡萄糖醛酸转移酶(UDPG),在胆红素的清除、葡萄糖醛酸化和胆汁盐的形成中发挥着重要作用。当UGT1A1表达异常,胆酸池失去平衡,胆酸的底物胆固醇含量超过胆汁溶解度时,胆固醇即结晶形成胆固醇结石。此外,当增多的胆红素与钙离子结合,也会因超过其溶解度而沉积加重胆泥[16]

3.2. 头孢曲松钠导致假性胆石症的特点有

1) 多见于大剂量(100 mg/(kg∙d)或更大)或长疗程使用时:随头孢曲松剂量增大,其在胆汁中的浓度会逐渐接近并超过溶解度上限,进一步沉淀后形成胆汁污泥。国内外相关学者通过分析头孢曲松相关胆囊结石患者的临床特点,得到结论:每日剂量(头孢曲松) > 2 g、疗程 5天以上被认为是成人(年龄 > 18岁)头孢曲松钠相关性胆囊结石发生的高危因素[17]-[19]。Biner等[6]通过分析156例头孢曲松钠相关假性胆囊结石儿童患者资料,发现头孢曲松剂量与假结石的发生率有明显相关性:超过2 g/d或100 mg/(kg∙d)应用后,假性结石的发生率较高,连续给药2~7天者的发生率较高。

2) 头孢曲松相关假性胆囊结石一般较小,和传统块状结石不同,假结石多呈泥沙样,在超声下,头孢曲松钙盐虽呈强回声,但其结构松散,在胆囊内的形态会因患者的体位变化而易变形,分散或如云絮样飘浮于胆汁中,而传统胆囊结石结构致密,不易变形,随患者体位改变而整体移动,在超声检查下后方伴声影[20]

3) 假结石的发生时间多在头孢曲松钠药后20小时~22天不等,最短可于给药次日即发现[20];本文所提供病例,患者于用药第9日,腹部CT检查时胆囊无异常,第15天因肺部感染复查胸部CT时,意外发现胆囊内高密度影,结合其胆囊结石形态特点,考虑为头孢曲松相关胆囊结石,遗憾的是胆囊结石真正形成的时间不得而知。

4) 头孢曲松相关胆囊结石患者无症状者居多。有报告无症状者可高达100%,仅少数病例表现为腹痛、呕吐甚至皮肤黄染症状[21] [22]

5) 之所以称为“假结石”,是因为几乎所有病例在停药后,胆囊结石均可自行逐渐消失,结石为可逆性。如前所述,假结石是形成因为胆囊内头孢曲松钙的浓度超过亚稳态极限,头孢曲松钙盐沉积所致,但结石本身结构并不稳定,在停药后,头孢曲松钙盐逐渐溶解到胆汁中排到肠道内,从而结石消失。Papadopoulou等报道在头孢曲松停药8~23天后,结石可自行消失[23]。Ozturk A等通过观察提出,结石完全溶解到消失至少要1个月[21]。Bor等[24]通过观察头孢曲松用药后14例胆石症及胆囊泥沙形成的小儿,停药30天复查,12例胆囊结石自行消失,2例胆囊超声仍有异常。然而,另有学者们提出其消失时间可能更长,最长可能需要2个月才可自行消退[1] [25]

4. 总结

头孢曲松钠是广谱杀菌药物,其机制是抑制细菌的细胞壁黏肽合成,最早于1982年在瑞士首次上市,因其抗菌谱广、半衰期长及较强的抗菌活性,迅速得到临床的广泛应用,很快在2年后获得美国FDA批准,广泛应用于敏感菌所致的呼吸道感染、消化道及腹腔感染、心内膜、皮肤和软组织、尿路等多部位的感染,以及用于重大手术的术前预防感染。本文所报道个案中,患者先后因胆管炎、胰腺炎、肺炎持续应用头孢曲松长达15天,虽其抗菌效果显著,但如此长时间的使用,也体现了本院临床医师对抗菌药物的选择、副作用等认知的不足。然而,随着头孢曲松钠相关性假性胆囊结石的报道不断增多,头孢曲松不良反应也引起越来越多临床医生的重视。值得注意的是,除本文阐述的假性胆囊结石外,头孢曲松的副作用尚包括严重的急性肾衰竭[26]-[28],虽然罕见,但在当今较为紧张的医疗环境下,仍然值得引起重视。

如前所述,头孢曲松相关假性胆囊结石多发生于长时间大剂量应用头孢曲松时,故临床医师应加强对其副作用的认知,准确把握用药时机及用药疗程,减少药物不良反应的发生率。一旦发现临床难以解释的新发结石,要耐心复习患者病历,如果考虑药物相关假性结石,要做好医患沟通,缓解患者紧张情绪,超声随访结石转归,防止不必要的追加药物治疗及胆囊切除。如前所述,本例患者于我院就诊第15天意外发现胆囊内高密度影,因患者本身无恶心、腹痛等胆系症状,考虑头孢曲松副作用故停药,未进一步其他处理,嘱患者随访观察,1个月后于当地医院复查消化系统超声未见胆囊内异常回声,提示结石消失。值得注意的是,Ito R等在高龄患者(80岁以上)身上也发现低剂量(≤2 g/天)头孢曲松诱导的假性胆囊结石[29],但遗憾的是,因缺乏体重信息,这些患者的单位体重剂量无法得到证实。因此,作为临床医师有必要记住,即使头孢曲松剂量在正常范围内,低体重患者或老年患者也可能会出现胆囊结石。

参考文献

[1] Schaad, U.B., Tschäppeler, H. and Lentze, M.J. (1986) Transient Formation of Precipitations in The Gallbladder Associated with Ceftriaxone Therapy. Pediatric Infectious Disease, 5, 708-709.
https://doi.org/10.1097/00006454-198611000-00026
[2] Jacobs, R.F. (1988) Ceftriaxone-Associated Cholecystitis. Pediatric Infectious Disease, 7, 434-435.
https://doi.org/10.1097/00006454-198806000-00018
[3] Ozturk, A., Kaya, M., Zeyrek, D., Ozturk, E., Kat, N. and Ziylan, S.Z. (2005) Ultrasonographic Findings in Ceftriaxone: Associated Biliary Sludge and Pseudolithiasis in Children. Acta Radiologica, 46, 112-116.
https://doi.org/10.1080/02841850510015983
[4] Acun, C., Erdem, L.O., Söğüt, A., et al. (2004) Gallbladder and Urinary Tract Precipitations Associated with Ceftriaxone Therapy in Children: A Prospective Study. Annals of Tropical Paediatrics, 24, 25-31.
https://doi.org/10.1179/027249304225013349
[5] Choi, Y.Y., Jung, Y.H., ChoI, S.M., Lee, C.S., Kim, D. and Hur, K.Y. (2011) Gallbladder Pseudolithiasis Caused By Ceftriaxone in Young Adult. Journal of the Korean Surgical Society, 81, 423-426.
https://doi.org/10.4174/jkss.2011.81.6.423
[6] Biner, B., Oner, N., Celtik, C., et al. (2006) Ceftriaxone-Associated Biliary Pseudolithiasis in Children. Journal of Clinical Ultrasound, 34, 217-222.
[7] Lee, S.P., Lipsky, B.A. and Teefey, S.A. (1990) Gallbladder Sludge and Antibiotics. The Pediatric Infectious Disease Journal, 9, 422-423.
https://doi.org/10.1097/00006454-199006000-00011
[8] Park, H.Z., Lee, S.P. and Schy, A.L. (1991) Ceftriaxone-Associated Gallbladder Sludge. Identification of Calcium-Ceftriaxone Salt as a Major Component of Gallbladder Precipitate. Gastroenterology, 100, 1665-1670.
https://doi.org/10.1016/0016-5085(91)90667-a
[9] 汪复, 张婴元. 实用抗感染治疗学[M]. 北京: 人民卫生出版社, 2020: 613.
[10] Stinton, L.M. and Shaffer, E.A. (2012) Epidemiology of Gallbladder Disease: Cholelithiasis and Cancer. Gut Liver, 6, 172-187.
https://doi.org/10.5009/gnl.2012.6.2.172
[11] Martin, E., Fanconi, S., Kälin, P., et al. (1993) Ceftriaxone-Bilirubin-Albumin Interactions in the Neonate: An in Vivo Study. European Journal of Pediatrics, 152, 530-534.
https://doi.org/10.1007/BF01955067
[12] Arpacik, M., Ceran, C., Kaya, T., Karadas, B., Sarac, B. and Koyluoğlu, G. (2004) Effects of Ceftriaxone Sodium on in Vitro Gallbladder Contractility in Guinea Pigs. Journal of Surgical Research, 122, 157-161.
https://doi.org/10.1016/j.jss.2004.05.020
[13] Araz, N., Okan, V., Demirci, M. and Araz, M. (2007) Pseudolithiasis Due to Ceftriaxone Treatment for Meningitis in Children: Report of 8 Cases. The Tohoku Journal of Experimental Medicine, 211, 285-290.
https://doi.org/10.1620/tjem.211.285
[14] Ozturk, A., Kaya, M., Zeyrek, D., Ozturk, E., Kat, N. and Ziylan, S.Z. (2005) Ultrasonographic Findings in Ceftriaxone: Associated Biliary Sludge and Pseudolithiasis in Children. Acta Radiologica, 46, 112-116.
https://doi.org/10.1080/02841850510015983
[15] Meng, D., Cao, Y., Fu, J., Chen, R., Lu, L. and Tu, Y. (2010) Sonographic Assessment of Ceftriaxone-Associated Biliary Pseudolithiasis in Chinese Children. Journal of International Medical Research, 38, 2004-2010.
https://doi.org/10.1177/147323001003800614
[16] Fretzayas, A., Liapi, O., Papadopoulou, A., Nicolaidou, P. and Stamoulakatou, A. (2011) Is Ceftriaxone-Induced Biliary Pseudolithiasis Influenced by UDP-Glucuronosyltransferase 1A1 Gene Polymorphisms? Case Reports in Medicine, 2011, Article ID: 730250.
https://doi.org/10.1155/2011/730250
[17] Soysal, A., Eraşov, K., Akpinar, I. and Bakir, M. (2007) Biliary Precipitation during Ceftriaxone Therapy: Frequency and Risk Factors. The Turkish Journal of Pediatrics, 49, 404-407.
[18] Acun, C., Erdem, L.O., Sogut, A., Erdem, C.Z., Tomac, N. and Gundogdu, S. (2004) Ceftriaxone-Induced Biliary Pseudolithiasis and Urinary Bladder Sludge. Pediatrics International, 46, 368-370.
https://doi.org/10.1111/j.1442-200x.2004.01900.x
[19] Rivera, M., GarcÍA-Herrera, A.L., Burguera, V., Sosa-Barrios, H., Palomares, J.R. and Quereda, C. (2011) Ceftriaxone-Associated Gallbladder Pseudolithiasis in a PD Patient. Peritoneal Dialysis International, 31, 97-99.
https://doi.org/10.3747/pdi.2010.00092
[20] 相龙彬. 头孢曲松钠导致假性胆石症二例[J]. 中华放射学杂志, 2007, 41(10): 1150.
[21] Ozturk, A., Kaya, M., Zeyrek, D., Ozturk, E., Kat, N. and Ziylan, S.Z. (2005) Ultrasonographic Findings in Ceftriaxone: Associated Biliary Sludge and Pseudolithiasis in Children. Acta Radiologica, 46, 112-116.
https://doi.org/10.1080/02841850510015983
[22] Palanduz, A., Yalçin, I., Tonguç, E., et al. (2000) Sonographic Assessment of Ceftriaxone-Associated Biliary Pseudolithiasis in Children. Journal of Clinical Ultrasound, 28, 166-168.
https://doi.org/10.1002/(SICI)1097-0096(200005)28:4%3C166::AID-JCU2%3E3.0.CO;2-G
[23] Papadopoulou, F., Efremidis, S., Karyda, S., et al. (1999) Incidence of Ceftriaxone-Associated Gallbladder Pseudolithiasis. Acta Paediatrica, 88, 1352-1355.
https://doi.org/10.1111/j.1651-2227.1999.tb01050.x
[24] Kirejczyk, W.M., Crowe, H.M., Mackay, I.M., Quintiliani, R. and Cronin, E.B. (1992) Disappearing “Gallstones”: Biliary Pseudolithiasis Complicating Ceftriaxone Therapy. American Journal of Roentgenology, 159, 329-330.
https://doi.org/10.2214/ajr.159.2.1632349
[25] Bor, O., Dinleyici, E.C., Kebapci, M. and Aydogdu, S.D. (2004) Ceftriaxone-Associated Biliary Sludge and Pseudocholelithiasis during Childhood: A Prospective Study. Pediatrics International, 46, 322-324.
https://doi.org/10.1111/j.1328-0867.2004.01884.x
[26] Akl, K.F., Masri, A.T. and Hjazeen, M.M. (2011) Acute Urineretention Induced by Ceftriaxone. Saudi Journal of Kidney Diseases and Transplantation, 22, 1226-1228.
[27] Li, Z.L., Li, H.L., Chen, H.W., et al. (2013) Anuria and Abdominal Pain Induced by Ceftriaxoneassociated Ureterolithiasis in Adults. International Urology and Nephrology, 45, 73-76.
https://doi.org/10.1007/s11255-012-0330-x
[28] Kapur, G., Valentini, R.P., Mattoo, T.K., Warrier, I. and Imam, A.A. (2008) Ceftriaxone Induced Hemolysiscomplicated by Acute Renal Failure. Pediatric Blood & Cancer, 50, 139-142.
https://doi.org/10.1002/pbc.20839
[29] Ito, R., Yoshida, A., Taguchi, K., Enoki, Y., Yokoyama, Y. and Matsumoto, K. (2019) Experimental Verification of Factors Influencing Calcium Salt Formation Based on a Survey of the Development of Ceftriaxone-Induced Gallstone-Related Disorder. Journal of Infection and Chemotherapy, 25, 972-978.
https://doi.org/10.1016/j.jiac.2019.05.020